A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
NCT07602855
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine: What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? How does the body handle the drug(s)? What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neoplasms, Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- September 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- GSK Investigational Site · Los Angeles, CA
North Carolina · 1
- GSK Investigational Site · Wilson, NC
Ohio · 1
- GSK Investigational Site · Canton, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.